Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

39

Revenue 2017

Orencia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Orencia was produced by Bristol-Myers Squibb.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro

Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and

Opdivo drives growth at BMS, but US sales slow down

Opdivo drives growth at BMS, but US sales slow down Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Opdivo drives gain in BMS sales, but business revamp coming

Opdivo drives gain in BMS sales, but business revamp coming Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.

Shire gives up on Momenta-partnered Humira biosimilar

Shire gives up on Momenta-partnered Humira biosimilar It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).

Deal Watch January 2016

Deal Watch January 2016 255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics